Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Subscribe To Our Newsletter & Stay Updated
